GRO Biosciences Inc. (“GRObio”), a pioneering biotechnology firm utilizing synthetic biology to enhance the amino acid repertoire and advance protein therapeutics, has successfully concluded an oversubscribed Series B financing round, raising $60.3 million. This funding milestone marks a significant step…
RefleXion Medical, a leader in external-beam theranostic oncology, has announced that researchers will present pioneering scientific findings in 37 oral and poster presentations at the 2024 American Association of Physicists in Medicine (AAPM) Annual Meeting in Los Angeles, July 21-25.…
Researchers have made a groundbreaking advance in cancer treatment by successfully using Seraph® 100 blood filtration media to remove Circulating Tumor Cells (CTCs) from patients with advanced pancreatic cancer. This breakthrough supports ExThera Medical’s ONCObind™ Procedure Hemoperfusion Filter (ONCObind™), designed…
Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF), a Canadian commercial dermatology company focused on growth and innovation, has announced the signing of an exclusive Manufacturing and Supply Agreement with a leading Canadian diversified healthcare services provider. This agreement…
Ora, a leading global contract research organization (CRO) specializing in ophthalmic research, has announced a strategic recapitalization by The Vistria Group, a middle-market private investment firm focused on delivering financial returns and societal impact. “The Vistria Group’s investment underscores their…
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) announced today the initiation of disbursement for the full monetization of a Standby Letter of Credit (“SBLC”). This initial disbursement marks the first payment under the arrangement, leading to a release of lien and…
Bristol Myers Squibb (NYSE: BMY) has announced that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a potential first-line treatment for adults with unresectable or advanced hepatocellular carcinoma (HCC)…
AscellaHealth, a global partner specializing in end-to-end solutions for life sciences and healthcare companies aimed at improving the quality of life for patients with complex, chronic conditions, has launched its latest edition of the Specialty & Rare Pipeline Digest™. This…
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), unveiled new four-year findings from the RHONE-X extension study today. The study successfully met all primary endpoints, underscoring the well-tolerated nature of Vabysmo® (faricimab-svoa) in individuals with diabetic…
Lynch Regenerative Medicine, LLC (LRM) has successfully concluded its Series A financing to advance innovative skin rejuvenation and regeneration solutions based on FDA-approved pure platelet-derived growth factor (PDGF). Champion VC, managing assets of the Frist family of Nashville, Tennessee, led…
CytoReason, a pioneer in computational disease models for predictive insights, has secured $80 million from OurCrowd, NVIDIA (Nasdaq: NVDA), Pfizer (NYSE: PFE), and Thermo Fisher Scientific (NYSE: TMO). “This investment underscores the potential of computational disease models to revolutionize data…
MedImpact Healthcare Systems, Inc., the nation’s largest independent provider of health solutions, technology, and pharmacy benefit management services, has announced the successful completion of the integration of Elixir Solutions. This strategic acquisition not only enhances MedImpact’s scale and expands its…